Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials

被引：0
|
作者：
Folprecht, G.
Seymour, M. T.
Saltz, L.
Douillard, J. Y.
Stephens, R. J.
Van Cutsem, E.
Rougier, P.
Maughan, T. S.
Koehne, C. H.
机构：
[1] Univ Hosp Dresden, Dresden, Germany
[2] Cookridge Hosp, Leeds, W Yorkshire, England
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Ctr R Gauducheau, Nantes, France
[5] MRC Clin Trials Unit, London, England
[6] Univ Hosp Gasthuisberg, Leuven, Belgium
[7] Hop Ambroise Pare, Boulogne, France
[8] Velindre Hosp, Cardiff, S Glam, Wales
[9] Klinikum Oldenburg GGmbH, Oldenburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4071
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Disease oriented treatment of metastatic colorectal cancer (CRC) with dose-dense 5-FU/Folinic acid (FU/FA) combination chemotherapy
    Loeffler, TM
    Droege, C
    Lenfers, BHM
    Hausamen, TU
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S73 - S73
  • [22] 5-FU/FA IV Bolus therapy vs weekly high-dose 5-FU/FA 24-hour infusion in metastatic colorectal carcinoma: Preliminary results of an ongoing randomized Phase III study
    Weh, HJ
    Hoffknecht, M
    Holzer, P
    Braumann, D
    Hoffman, R
    Gellermann, HJ
    Becker, K
    Mullerleile, U
    Drescher, S
    Hossfeld, DK
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 754 - 754
  • [23] Randomized phase III trial comparing infused irinotecan 5-fluorouracil (5-FU) folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)
    Van Cutsem, E
    Labianca, R
    Hossfeld, D
    Bodoky, G
    Roth, A
    Aranda, E
    Nordlinger, B
    Assadourian, S
    Wang, K
    Cunningham, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1090S - 1090S
  • [24] The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
    Scartozzi, M
    Sobrero, A
    Gasparini, G
    Berardi, R
    Catalano, V
    Graziano, F
    Barni, S
    Zaniboni, A
    Beretta, GD
    Labianca, R
    Cascinu, S
    ONCOLOGY, 2005, 68 (2-3) : 212 - 216
  • [25] Whole body hyperthermia (WBH, 41.8°C) as an adjunct to oxaliplatin (OXA)/5-FU/FA in high-dose (HD)-5-FU/FA or HD-5-FU/FA and CPT-11 refractory/relapsed advanced colorectal cancer.
    Hegewisch-Becker, S
    Gruber, Y
    Panse, J
    Atanackovic, D
    Nierhaus, A
    Hossfeld, DK
    ANNALS OF ONCOLOGY, 2000, 11 : 61 - 61
  • [26] Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer:: Meta-analysis of four trials investigating 5-FU and irinotecan.
    Folprecht, G.
    Rougier, P.
    Saltz, L.
    Van Cutsem, E.
    Douillard, J. Y.
    Sastre, J.
    Mitry, E.
    Hecker, H.
    Schubert, U.
    Köhne, C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 165S - 165S
  • [27] A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma
    Graeven, Ullrich
    Arnold, Dirk
    Reinacher-Schick, Anke
    Heuer, Theodor
    Nusch, Arnd
    Porschen, Rainer
    Schmiegel, Wolff
    ONKOLOGIE, 2007, 30 (04): : 169 - 174
  • [28] Pilot trial of 5-FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (IFL).
    Aparicio, A
    Iqbal, S
    Yang, D
    Groshen, S
    Park, D
    Garcia, A
    Lenz, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 312S - 312S
  • [29] Phase I of CPT-11 (CAMPTO®) combined with 5-FU/folinic acid (FA) nordic schedule in first line metastatic colorectal cancer (CRC)
    Ristamäki, R
    Glimelius, B
    Linné, T
    Boussard, B
    Oulid-Aïssa, D
    Pyrhonen, S
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S79 - S79
  • [30] 5-fluorouracil (5-FU),folinic acid (FA) and oxaliplatin (FUFOX) as second chemotherapy in patients with metastatic colorectal cancer (MCRC)
    Andric, Z.
    Murtezani, Z.
    Kovcin, V
    Gutovic, J.
    Kostic, S.
    ANNALS OF ONCOLOGY, 2006, 17 : 66 - 67
12345